NCT05183984 2026-04-13
NIRVANA-1
ARCAGY/ GINECO GROUP
Phase 2 Recruiting
Clinical Trials
14 trialsNCT06915025 2026-04-13
OVATION-3
Imunon
Phase 3 Recruiting
NCT06412120 2026-03-16
Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
University of Miami
Phase 4 Recruiting
NCT03651206 2025-12-19
ROCSAN
ARCAGY/ GINECO GROUP
Phase 2/3 Recruiting
NCT06180356 2025-11-28
ANALLISA
MedSIR
Phase 2 Recruiting
NCT04641247 2025-09-29
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
GlaxoSmithKline
Phase 2 Recruiting
NCT05009082 2025-09-10
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
AGO Study Group
Phase 3 Recruiting
NCT05990192 2025-04-22
SOPRANO
Institute of Cancer Research, United Kingdom
Phase 2 Recruiting
NCT06827353 2025-02-14
OVNI-B
Centre Hospitalier Universitaire de NÄ«mes
Recruiting
NCT06614790 2024-10-23
NIRAPARIB
Pomeranian Medical University Szczecin
Recruiting
NCT04716686 2024-01-05
Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Shandong University
Phase 2 Recruiting
NCT05961124 2023-11-22
Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
Sunnybrook Health Sciences Centre
Phase 2 Recruiting
NCT06141265 2023-11-21
BRAND
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT03983226 2022-03-18
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
Shanghai Gynecologic Oncology Group
Phase 2 Recruiting